Pharmagreen Biotech Stock Net Income
| PHBI Stock | USD 0 0.0001 5.26% |
Pharmagreen Biotech fundamentals help investors to digest information that contributes to Pharmagreen Biotech's financial success or failures. It also enables traders to predict the movement of Pharmagreen Pink Sheet. The fundamental analysis module provides a way to measure Pharmagreen Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Pharmagreen Biotech pink sheet.
Pharmagreen |
Pharmagreen Biotech Company Net Income Analysis
Pharmagreen Biotech's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Pharmagreen Biotech Net Income | (875.48 K) |
Most of Pharmagreen Biotech's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Pharmagreen Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Pharmagreen Biotech reported net income of (875,478). This is 100.26% lower than that of the Healthcare sector and significantly lower than that of the Drug Manufacturers—Specialty & Generic industry. The net income for all United States stocks is 100.15% higher than that of the company.
Pharmagreen Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Pharmagreen Biotech's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Pharmagreen Biotech could also be used in its relative valuation, which is a method of valuing Pharmagreen Biotech by comparing valuation metrics of similar companies.Pharmagreen Biotech is currently under evaluation in net income category among its peers.
Pharmagreen Fundamentals
| Return On Asset | -2.3 | |||
| Current Valuation | 3.12 M | |||
| Shares Outstanding | 454.76 M | |||
| Shares Owned By Insiders | 18.63 % | |||
| EBITDA | (828.26 K) | |||
| Net Income | (875.48 K) | |||
| Cash And Equivalents | 24.26 K | |||
| Total Debt | 119.47 K | |||
| Current Ratio | 0.10 X | |||
| Book Value Per Share | (0) X | |||
| Cash Flow From Operations | (426.57 K) | |||
| Earnings Per Share | (0.01) X | |||
| Beta | 1.44 | |||
| Market Capitalization | 2.96 M | |||
| Total Asset | 208.97 K | |||
| Z Score | 4.5 | |||
| Net Asset | 208.97 K |
About Pharmagreen Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Pharmagreen Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pharmagreen Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pharmagreen Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Pharmagreen Pink Sheet
Pharmagreen Biotech financial ratios help investors to determine whether Pharmagreen Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Pharmagreen with respect to the benefits of owning Pharmagreen Biotech security.